Skip to main content
Equibles
RXST logo

RXST · RxSight, Inc.

Track RXST — free

Use RXST with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RXST.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.32 -0.06 (-1.12%) At close · Nov 13
Russell 2000 member Rebalance outlook locked
Customer concentration — top customer 10% of receivables

One customer — 10% of receivables (September 30, 2026)

“As of September 30, 2026, the Company had one customer who individually accounted for greater than 10% of trade accounts receivable.”
View the 10-Q filed Nov 3, 2026
Market Cap
$223.06M
Shares
41.93M
Volume · Nov 13 534.56K Avg daily vol (3M) 823.37K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.32 Open$5.45 Day$5.29–5.63 52W close$4.51–13.09 Avg vol 30d849K Short int3.6M · 8.7% of shares · 6.1d Short vol32% Last earningsNov 3, 2026 DataJul 2021–Nov 2026 Filing10-Q · Nov 3

Up next

Next earnings call
Jan 8, 2027 Est · unconfirmed · in 8 wks
Q3 2026 earnings call transcript
call held Nov 3, 2026
Play latest call

Latest documents

2026
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue Declines Amid Stronger Competition

RxSight quarterly revenue fell 19.0% to $24.6 million as lower LDD and LAL sales reflected increased competition. Its $50.0 million Alcon upfront payment became nonrefundable on October 28, 2026.

Revenue $24.59M ▼ 19.0% Net loss $16.22M Diluted EPS -$0.39
Read from the MD&A section
4 source passages
Total revenue for the three months ended September 30, 2026, was $24.6 million, a decrease of $5.8 million, or 19.0%, compared to $30.3 million for the three months ended September 30, 2025. The decrease in product sales was primarily due to lower unit sales of both LDDs and LALs, reflecting, among other things, increased competition in the IOL market, including recent widespread competitive trialing activity for new product launches. We accounted for the RxSight-Alcon Collaboration Agreement under ASC Topic 606 and ASC Topic 808. Our current liabilities as of September 30, 2026 included a $50.0 million refund liability, representing the portion of the upfront payment under the RxSight-Alcon Collaboration Agreement that was refundable if the agreement was terminated within 120 days of its effective date. The 120-day period ended on October 28, 2026 without termination of the agreement, and such amount is no longer refundable. Open the document at this passage
Nov 3
Current report 8-K
Third-quarter 2026 revenue falls 19% as loss widens

RxSight reported third-quarter 2026 revenue of $24.6 million, down 19% from the prior-year period, and a net loss of $(16.2) million, or $(0.39) per basic and diluted share.

Financial results
2 source passages
In the third quarter of 2026, total revenue was $24.6 million, down 19% from the prior-year period, primarily reflecting ongoing competitive pressures. In the third quarter, the company reported a net loss of $(16.2) million, or $(0.39) per basic and diluted share, compared to a net loss of $(9.8) million, or $(0.24) per basic and diluted share in the third quarter of 2025. Open the document at this passage
Sep 8
Tender offer SC TO-I/A
Tender offer AI summary on its way
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$121.83M
Trailing 12 months
Net income (TTM)
−$53.36M
Trailing 12 months
Revenue growth YoY
-19.0%
Year over year
Operating margin
-50.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
8.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.8%
Year over year · more shares
Price change (1Y)
-44.5%
Trailing year
Short interest
8.7%
Latest settlement · 6.1 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲40.7% $40.21M −$5.94M '24 Q4* ▲28.4% $37.90M −$8.19M '25 Q1 ▼3.6% $33.64M −$11.79M '25 Q2 ▼14.1% $30.34M −$9.82M '25 Q3 ▼18.9% $32.61M −$9.15M '25 Q4* ▼18.5% $30.89M −$15.88M '26 Q1 ▲0.3% $33.74M −$12.10M '26 Q2 LATEST ▼19% $24.59M −$16.22M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. RxSight (RXST) reported Q2 2026 total revenue of $33.7 million but product sales fell 19% year-over-year on competitive trialing, and management withdrew its previously issued full-year 2026 financial guidance while it completes a strategic review under new CEO Aziz Mottiwala.

Bullish
  • + Entered Alcon strategic collaboration with up to $200M in upfront and milestone payments and future royalty potential
  • + Expects to recognize $30-40M of revenue from the Alcon collaboration over the remainder of 2026
  • + Approved plan to double the U.S. sales force over time, funded primarily by reallocating resources
  • + Cash position strengthened by ~$209M plus a $60M receivable from Alcon received after quarter end
  • + Plans next-generation LAL, LAL+ and LAL Toric lenses to improve workflow and reduce postoperative visits
Bearish
  • − Q2 product sales fell 19% year-over-year due to competitive trialing and broader marketplace headwinds
  • − Withdrew previously issued full-year 2026 financial guidance; will resume guidance in early 2027
  • − Product gross margin contracted to 71.2% from 74.9% on higher inventory-related costs
  • − LAL unit volumes declined 9% year-over-year
  • − Only 12 LDD units placed in the quarter against an installed base of 1,166

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Mentioned in fund letters

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −13%
below
Price vs 50-day avg +6%
above
RSI (14) 59
neutral
MACD trend Positive
52-week position 9%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +18%
trailing
6-month return −11%
trailing
YTD return −49%
this year
Relative strength −12%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $5 › 200d $6 — 200d above 50d
Institutional flow Distributing
109 of 151 funds reported for Sep 30 · net -2.1M sh shares · +16 new
Insider flow Distributing
Net -$118.0K over 90 days · 100% sells
Short interest Falling
8.67% of shares out · ▼ -11.8% MoM · 6.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
151 holders — mid 3-yr range
Squeeze score 73
high risk · 0–100
Fundamentals
Weak
Revenue growth −4%
Y/Y
Gross margin 77%
expanding
EPS growth −34%
Y/Y
Free cash flow $-19.3M
Quant / Vol
risk profile
Very High
Volatility 63%
annualized · 1-yr
Max drawdown −66%
past year
ATR 6.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 6
Latest guidance · from the Earnings Call filed Aug 5, 2026
Revenue associated with the Alcon Strategic Agreement · remainder of the year $30M – $40M
Previous outlook earlier release · from the Earnings Call filed Jul 7, 2026

Still-open targets the latest release did not restate under the same label.

RxSight sales · full year 2026 $110M – $120M
RxSight Alcon Strategic Collaboration revenue · full year 2026 $30M – $40M
Guided vs delivered · last 6 settled
Revenue full-year 2025
guided $125M – $130M
$134.48M Beat +5.5%
Q4 revenues Q4 2025
guided $23M – $28M
$32.61M Beat +27.9%
Revenue 2024 full-year
guided $139M – $140M
$139.93M In line
Revenue full-year 2023
guided $85M – $87M
$89.08M Beat +3.6%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−13% Bearish
Price vs 50-day avg
+6% Bullish
RSI (14)
59 Neutral
MACD trend
Positive Bullish
52-week position
9% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $5 › 200d $6 — 200d above 50d
Institutional flow Distributing
109 of 151 funds reported for Sep 30 · net -2.1M sh shares · +16 new
Insider flow Distributing
Net -$118.0K over 90 days · 100% sells
Short interest Falling
8.67% of shares out · ▼ -11.8% MoM · 6.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
151 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5 Now $5 · 9% Range high $13
vs 200-day avg -13% vs 50-day avg +6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Installed Base at End of Period 1,166 Q2 2026 filing —
LALs Sold 24,917 Q2 2026 filing —
LDDs Sold 11 Q2 2026 filing —
Light Adjustable Lens (LAL) units -24,917 Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RXST
RxSight, Inc.
this stock
$223.06M -48.9% -3.9% — 8.7%
ABT
Abbott Laboratories
 $187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
 $131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
 $117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
 $64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
155
% held
93.8%
Reported
109 of 151
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
131
View
Short & Settlement
Short Interest Falling
Shares short
3.6M
Days to cover
6.1d
Change
-485.2K sh
View
Short Volume
Short vol %
32%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
1.1K
Value
$5.3K
As of
Oct 7, 2026
View
Off-Exchange
Off-exchange %
33.7%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$118.0K
Buyers / Sellers
0 / 4
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$134.5M
Net income (FY)
$-38.9M
EPS diluted
$-0.95
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 3, 2026
This year
23

RxSight quarterly revenue fell 19.0% to $24.6 million as lower LDD and LAL sales reflected increased competition. Its $50.0 million Alcon upfront payment became nonrefundable on October 28, 2026.

View
Proposed Sales
Value
$35.5K
Shares
5.1K
Filed
Sep 2, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 3, 2026
View
Investor Relations
Latest news
RxSight, Inc. Reports Third Quart…
Published
Nov 3, 2026
View

Performance

5D 20D 120D MTD YTD
RXST +17.2% +18.0% -11.2% +9.2% -48.9%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +14.6% +19.1% -11.7% +9.4% -59.6%
Key facts CIK 1111485 CUSIP 78349D107 13F (30d) 104 filings 90 filers Visit website Investor relations